KL (6431) reported revenue of NT$41.4 million for Oct 2026, +53.0% year on year and -23.4% from the previous month. Revenue for Jan–Oct 2026 was NT$357.9 million (+20.7% year on year).
Year-on-year revenue growth: 5 months in a row. →
In Oct 2026, it ranked No. 106 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$41.4 million | +53.0% | -23.4% |
| Sep 2026 | NT$54 million | +42.9% | +29.0% |
| Aug 2026 | NT$41.9 million | +185.9% | +17.2% |
| Jul 2026 | NT$35.7 million | +101.7% | +19.5% |
| Jun 2026 | NT$29.9 million | +37.1% | +7.7% |
| May 2026 | NT$27.8 million | -23.2% | -33.4% |
| Apr 2026 | NT$41.7 million | +31.2% | +60.4% |
| Mar 2026 | NT$26 million | -32.1% | +18.4% |
| Feb 2026 | NT$21.9 million | -15.6% | -41.5% |
| Jan 2026 | NT$37.5 million | -16.8% | -8.5% |
| Dec 2025 | NT$41 million | +0.0% | -8.5% |
| Nov 2025 | NT$44.8 million | +54.3% | +65.5% |
| Oct 2025 | NT$27.1 million | -48.9% | -28.5% |
| Sep 2025 | NT$37.8 million | +8.7% | +158.1% |
| Aug 2025 | NT$14.7 million | -68.2% | -17.3% |
| Jul 2025 | NT$17.7 million | -23.3% | -18.8% |
| Jun 2025 | NT$21.8 million | -10.2% | -39.7% |
| May 2025 | NT$36.2 million | +42.1% | +13.9% |
| Apr 2025 | NT$31.8 million | -20.4% | -17.0% |
| Mar 2025 | NT$38.3 million | +30.6% | +47.4% |
| Feb 2025 | NT$26 million | +167.0% | -42.3% |
| Jan 2025 | NT$45.1 million | +94.0% | +10.0% |
| Dec 2024 | NT$41 million | +151.1% | +41.3% |
| Nov 2024 | NT$29 million | +8.9% | -45.2% |
| Oct 2024 | NT$52.9 million | +58.3% | +52.0% |
Jan–Oct 2026 cumulative: NT$357.9 million (+20.7% YoY)
Other Biotech & Medical companies
Compare with peers: KL vs PEC / KL vs Lotus Pharm / KL vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
本年有新增子公司,故營業收入較去年同期 增加。
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16